ImmunityBio, Inc.

Background

Company Name	ImmunityBio, Inc.
Stock Symbol	IBRX
Class Period	January 19, 2026 to March 24, 2026
Lead Plaintiff Motion Deadline	May 26, 2026

Submit Your Information

If you suffered a loss on your ImmunityBio, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 19, 2026?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On March 24, 2026, Bloomberg reported that ImmunityBio had received a Warning Letter from the U.S. Food and Drug Administration (“FDA”) stating that the Company’s Executive Chairman and Global Chief Scientific and Medical Officer, Patrick Soon-Shiong, made inaccurate claims on a podcast regarding the Company’s lead biologic product, Anktiva, including that the drug “can cure and even prevent all cancer.” The FDA thus “determined that the TV ad and podcast are false or misleading” and “make the distribution of the drug in violation of the Federal Food, Drug, and Cosmetic Act.”

On this news, ImmunityBio’s stock price fell $1.98, or 21.12%, to close at $7.42 per share on March 24, 2026, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendant Soon-Shiong materially overstated Anktiva’s capabilities; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Submit Your Information